Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 2026 Financial Results
Dianthus Therapeutics reported a strengthened balance sheet with approximately $1.2 billion in cash as of March 31, 2026, providing runway into 2030 following a $719 million public offering. The company achieved an early GO decision in the Phase 3 CAPTIVATE trial for CIDP after identifying 20 confirmed responders with fewer than 40 participants completing Part A. Claseprubart received FDA Orphan Drug Designation for Myasthenia Gravis, and the Phase 3 EMERGE trial remains on track to initiate in mid-2026.
Key figures
- Revenue
- 463000
- Net loss
- 40834000
- Rd expenses
- 34528000
- Cash position
- 1200000000
- Offering proceeds
- 719000000
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.